The Gastroenterology Group, PC, Announces Expansion into Clinical Research
Reston, Va., Feb. 20, 2018 (Business Wire)-The Gastroenterology Group, PC, a gastroenterology practice based in Reston, Va., announces its expansion into clinical research by partnering with Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients.
The Gastroenterology Group is now offering clinical trials, allowing it to introduce the latest advances in research to its patients. As a result, the clinic’s patients have access - in the convenience of the clinic’s office - to treatments they might not otherwise have. The Gastroenterology Group recognizes the importance of conducting clinical research for its patients and community and doing its part to advance health care around the world.
“As a practice on the forefront of medicine, we are pleased to be able to offer clinical trials as treatment options for our patients. This will give our patients access to novel therapies that they would otherwise not have,” said Emil E. Valle, M.D., of The Gastroenterology Group. “Expanding treatment options for conditions, such as inflammatory bowel disease, is extremely important to provide optimal care. It was Elligo’s unique approach of providing clinical trial infrastructure at no cost that made offering trials feasible. We look forward to being a part of the Elligo network.”
“Elligo is delighted to be working with The Gastroenterology Group to advance the care its physicians are offering to patients,” said John Potthoff, Ph.D., co-founder and CEO of Elligo Health Research. “We provide the personnel, processes, technology and infrastructure to make the clinical research process easier for clinics at no cost, so they can focus on taking care of patients.”
About The Gastroenterology Group, PC
At The Gastroenterology Group, we believe that each patient and doctor becomes a team for treating an individual's digestive problems. Our gastroenterologists spend most of their time listening to understand your concerns and to respond with the best treatment options for you. Our professional staff understands the importance of following up to make sure that problems are resolved and your health improves.
CONTACT:
Lea Studer
SCORR Marketing
402-366-1752
lea@scorrmarketing.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
